Literature DB >> 23992036

Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.

Xiomara A Perez1, J Michael McIntosh, Maryka Quik.   

Abstract

Long-term nicotine exposure induces alterations in dopamine transmission in nucleus accumbens that sustain the reinforcing effects of smoking. One approach to understand the adaptive changes that arise involves measurement of endogenous dopamine release using voltammetry. We therefore treated rats for 2-3 months with nicotine and examined alterations in nAChR subtype expression and electrically evoked dopamine release in rat nucleus accumbens shell, a region key in addiction. Long-term nicotine treatment selectively decreased stimulated α6β2* nAChR-mediated dopamine release compared with vehicle-treated rats. It also reduced α6β2* nAChRs, suggesting the receptor decline may contribute to the functional loss. This decreased response in release after chronic nicotine treatment was still partially sensitive to the agonist nicotine. Studies with an acetylcholinesterase inhibitor demonstrated that the response was also sensitive to increased endogenous acetylcholine. However, unlike the agonists, nAChR antagonists decreased dopamine release only in vehicle- but not nicotine-treated rats. As antagonists function by blocking the action of acetylcholine, their ineffectiveness suggests that reduced acetylcholine levels partly underlie the dampened α6β2* nAChR-mediated function in nicotine-treated rats. As long-term nicotine modifies dopamine release by decreasing α6β2* nAChRs and their function, these data suggest that interventions that target this subtype may be useful for treating nicotine dependence. Long-term nicotine treatment decreases dopamine (DA) transmission in the mesolimbic dopaminergic system. Our data suggest this may involve a decrease in α6β2* nicotinic receptor expression and function. These changes may play a key role in nicotine reward and dependence.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  addiction; nicotine; nicotinic receptors; nucleus accumbens; voltammetry

Mesh:

Substances:

Year:  2013        PMID: 23992036      PMCID: PMC3859710          DOI: 10.1111/jnc.12442

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  58 in total

1.  The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine.

Authors:  W A Corrigall; K B Franklin; K M Coen; P B Clarke
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission.

Authors:  R Exley; S J Cragg
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

3.  Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

Authors:  Xiomara A Perez; Neeraja Parameswaran; Luping Z Huang; Kathryn T O'Leary; Maryka Quik
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

Review 4.  Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake.

Authors:  R M Wightman; J B Zimmerman
Journal:  Brain Res Brain Res Rev       Date:  1990 May-Aug

5.  Neurochemical characterization of the release and uptake of dopamine in ventral tegmental area and serotonin in substantia nigra of the mouse.

Authors:  Carrie E John; Evgeny A Budygin; Yolanda Mateo; Sara R Jones
Journal:  J Neurochem       Date:  2005-11-21       Impact factor: 5.372

6.  Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.

Authors:  M R Picciotto; M Zoli; R Rimondini; C Léna; L M Marubio; E M Pich; K Fuxe; J P Changeux
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

7.  Regional variation in the effects of nicotine on catecholamine overflow in rat brain.

Authors:  M E Benwell; D J Balfour
Journal:  Eur J Pharmacol       Date:  1997-04-23       Impact factor: 4.432

8.  Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization.

Authors:  Andrew R Tapper; Sheri L McKinney; Raad Nashmi; Johannes Schwarz; Purnima Deshpande; Cesar Labarca; Paul Whiteaker; Michael J Marks; Allan C Collins; Henry A Lester
Journal:  Science       Date:  2004-11-05       Impact factor: 47.728

Review 9.  Dopamine and drug addiction: the nucleus accumbens shell connection.

Authors:  Gaetano Di Chiara; Valentina Bassareo; Sandro Fenu; Maria Antonietta De Luca; Liliana Spina; Cristina Cadoni; Elio Acquas; Ezio Carboni; Valentina Valentini; Daniele Lecca
Journal:  Neuropharmacology       Date:  2004       Impact factor: 5.250

Review 10.  Guidelines on nicotine dose selection for in vivo research.

Authors:  Shannon G Matta; David J Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward D Levin; Ronald J Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

View more
  14 in total

1.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

Review 2.  The striatal cholinergic system in L-dopa-induced dyskinesias.

Authors:  X A Perez; T Bordia; M Quik
Journal:  J Neural Transm (Vienna)       Date:  2018-02-28       Impact factor: 3.575

3.  Chronic Nicotine Mitigates Aberrant Inhibitory Motor Learning Induced by Motor Experience under Dopamine Deficiency.

Authors:  Jessica L Koranda; Anne C Krok; Jian Xu; Anis Contractor; Daniel S McGehee; Jeff A Beeler; Xiaoxi Zhuang
Journal:  J Neurosci       Date:  2016-05-11       Impact factor: 6.167

4.  r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.

Authors:  Joshua S Beckmann; Andrew C Meyer; M Pivavarchyk; David B Horton; Guangrong Zheng; Andrew M Smith; Thomas E Wooters; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

5.  Acute ethanol inhibits dopamine release in the nucleus accumbens via α6 nicotinic acetylcholine receptors.

Authors:  Nathan D Schilaty; David M Hedges; Eun Young Jang; Ryan J Folsom; Jordan T Yorgason; J Michael McIntosh; Scott C Steffensen
Journal:  J Pharmacol Exp Ther       Date:  2014-03-18       Impact factor: 4.030

Review 6.  Rodent models for nicotine withdrawal.

Authors:  Ranjithkumar Chellian; Azin Behnood-Rod; Dawn M Bruijnzeel; Ryann Wilson; Vijayapandi Pandy; Adriaan W Bruijnzeel
Journal:  J Psychopharmacol       Date:  2021-04-22       Impact factor: 4.562

7.  Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal.

Authors:  Xiomara A Perez; Taline V Khroyan; J Michael McIntosh; Maryka Quik
Journal:  Pharmacol Res Perspect       Date:  2014-12-16

Review 8.  Striatal cholinergic interneuron regulation and circuit effects.

Authors:  Sean Austin O Lim; Un Jung Kang; Daniel S McGehee
Journal:  Front Synaptic Neurosci       Date:  2014-10-21

Review 9.  Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease.

Authors:  George E Barreto; Alexander Iarkov; Valentina Echeverria Moran
Journal:  Front Aging Neurosci       Date:  2015-01-09       Impact factor: 5.750

10.  Efficient expression of functional (α6β2)2β3 AChRs in Xenopus oocytes from free subunits using slightly modified α6 subunits.

Authors:  Carson Kai-Kwong Ley; Alexander Kuryatov; Jingyi Wang; Jon Martin Lindstrom
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.